MyFinsight
Home
Blog
About
Proceeds from sales and
maturities of marketable...
$34,850K
Net cash (used in)
provided by investing...
$33,311K
Canceled cashflow
$1,539K
Net increase
(decrease) in cash, cash...
-$25,212K
Canceled cashflow
$33,311K
Non-cash stock-based
compensation
$8,238K
Prepaid expenses and
other current assets
-$5,911K
Accrued expenses and
other liabilities
$4,161K
Depreciation and
amortization
$3,224K
Non-cash lease expense
$2,692K
Proceeds from exercise of
stock options
$414K
Purchases of property and
equipment
$933K
Purchase of marketable
securities
$606K
Net cash used in
operating activities
-$57,944K
Canceled cashflow
$24,226K
Net cash provided by
financing activities
-$579K
Canceled cashflow
$414K
Net loss
-$67,255K
Deferred revenue
-$6,314K
Other assets
$4,312K
Accounts payable
-$1,954K
Operating lease
liabilities
-$1,948K
Amortization and accretion on
marketable securities
$387K
Payments on finance lease
obligations
$993K
Back
Back
Cash Flow
Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. (GENB)
source: myfinsight.com